Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

The lawsuit also claims that ProfoundBio 'cashed out' by advertising the trade secrets as its own inventions, attracting Genmab's attention, which agreed a $1.8 billion deal to buy the company ...